Squarepoint’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-253,193
| Closed | -$33.4M | – | 5231 |
|
|
2025
Q1 | $33.4M | Buy |
253,193
+103,017
| +69% | +$12.8M | 0.04% | 474 |
|
|
2024
Q4 | $12.5M | Sell |
150,176
-167,578
| -53% | -$13.8M | 0.01% | 1023 |
|
|
2024
Q3 | $23.3M | Buy |
317,754
+56,121
| +21% | +$4.22M | 0.04% | 530 |
|
|
2024
Q2 | $17.9M | Buy |
261,633
+137,432
| +111% | +$9.53M | 0.03% | 638 |
|
|
2024
Q1 | $8.59M | Buy |
124,201
+83,072
| +202% | +$5.71M | 0.01% | 1096 |
|
|
2023
Q4 | $2.95M | Sell |
41,129
-43,065
| -51% | -$2.48M | 0.01% | 1745 |
|
|
2023
Q3 | $4.39M | Buy |
+84,194
| New | +$4.9M | 0.01% | 1262 |
|
|
2023
Q2 | – | Sell |
-26,260
| Closed | -$1.42M | – | 4111 |
|
|
2023
Q1 | $1.42M | Buy |
+26,260
| New | +$1.27M | 0.01% | 1652 |
|
|
2022
Q4 | – | Sell |
-17,410
| Closed | -$810K | – | 3689 |
|
|
2022
Q3 | $810K | Buy |
+17,410
| New | +$909K | ﹤0.01% | 1903 |
|
|
2022
Q1 | – | Sell |
-5,815
| Closed | -$304K | – | 3659 |
|
|
2021
Q4 | $304K | Buy |
+5,815
| New | +$244K | ﹤0.01% | 2449 |
|
|
2021
Q3 | – | Sell |
-8,198
| Closed | -$335K | – | 3541 |
|
|
2021
Q2 | $335K | Buy |
+8,198
| New | +$303K | ﹤0.01% | 2449 |
|
|
2021
Q1 | – | Sell |
-10,728
| Closed | -$341K | – | 3714 |
|
|
2020
Q4 | $341K | Sell |
10,728
-33,746
| -76% | -$887K | ﹤0.01% | 2118 |
|
|
2020
Q3 | $1.14M | Buy |
+44,474
| New | +$1.01M | 0.02% | 921 |
|
|
2020
Q2 | – | Sell |
-12,134
| Closed | -$186K | – | 2570 |
|
|
2020
Q1 | $186K | Buy |
+12,134
| New | +$264K | ﹤0.01% | 1500 |
|
|
2019
Q4 | – | Sell |
-147,257
| Closed | -$1.1M | – | 2879 |
|
|
2019
Q3 | $1.1M | Buy |
147,257
+93,712
| +175% | +$899K | 0.01% | 1168 |
|
|
2019
Q2 | $695K | Buy |
53,545
+13,976
| +35% | +$179K | 0.01% | 1472 |
|
|
2019
Q1 | $482K | Buy |
39,569
+14,203
| +56% | +$181K | 0.01% | 1502 |
|
|
2018
Q4 | $289K | Buy |
25,366
+799
| +3% | +$12.9K | ﹤0.01% | 1527 |
|
|
2018
Q3 | $533K | Sell |
24,567
-15,899
| -39% | -$332K | 0.01% | 1270 |
|
|
2018
Q2 | $715K | Sell |
40,466
-4,934
| -11% | -$100K | 0.01% | 1030 |
|
|
2018
Q1 | $956K | Buy |
+45,400
| New | +$884K | 0.02% | 823 |
|
|
2017
Q4 | – | Sell |
-16,505
| Closed | -$260K | – | 2386 |
|
|
2017
Q3 | $260K | Buy |
+16,505
| New | +$242K | 0.01% | 1249 |
|
|
2017
Q1 | – | Sell |
-20,270
| Closed | -$306K | – | 1962 |
|
|
2016
Q4 | $306K | Buy |
20,270
+9,407
| +87% | +$133K | 0.01% | 1145 |
|
|
2016
Q3 | $166K | Buy |
+10,863
| New | +$439K | 0.01% | 918 |
|
|
2016
Q1 | – | Sell |
-7,000
| Closed | -$377K | – | 1491 |
|
|
2015
Q4 | $377K | Buy |
+7,000
| New | +$353K | 0.04% | 691 |
|
Other funds holding ITCI
Squarepoint's ITCI Position: Q2 2025 in Review
Squarepoint sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 253,193 shares — an estimated $33.4M sold.
Squarepoint first reported a position in ITCI in Q4 2015 and held it in 25 quarters. The position peaked at $33.4M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Squarepoint reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Squarepoint sold 253,193 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $33.4M.
- Squarepoint first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 25 quarters.
- Squarepoint's Intra-Cellular Therapies Inc. position peaked at $33.4M in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.